Analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.
OncoCyte Price Performance
Shares of OCX stock opened at $2.90 on Friday. OncoCyte has a 1-year low of $2.08 and a 1-year high of $7.20. The stock has a 50-day moving average of $2.98 and a 200-day moving average of $3.08.
Hedge Funds Weigh In On OncoCyte
A number of large investors have recently modified their holdings of OCX. Cubist Systematic Strategies LLC bought a new stake in shares of OncoCyte during the 2nd quarter valued at about $25,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of OncoCyte during the first quarter valued at approximately $25,000. Renaissance Technologies LLC raised its holdings in OncoCyte by 131.7% in the 2nd quarter. Renaissance Technologies LLC now owns 138,100 shares of the company’s stock worth $32,000 after acquiring an additional 78,500 shares during the last quarter. DCF Advisers LLC boosted its stake in OncoCyte by 107.0% during the 1st quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after purchasing an additional 13,000 shares during the last quarter. Finally, Balyasny Asset Management LLC increased its holdings in shares of OncoCyte by 389.9% in the 3rd quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock worth $39,000 after purchasing an additional 42,091 shares in the last quarter. 55.35% of the stock is owned by hedge funds and other institutional investors.
OncoCyte Company Profile
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Featured Stories
- Five stocks we like better than OncoCyte
- Stock Splits, Do They Really Impact Investors?
- Beazer Homes USA is an Overlooked Opportunity in Housing
- How to Use the MarketBeat Stock Screener
- 5 Stocks in the Current Bull Market with Upside to Come
- Stock Sentiment Analysis: How it Works
- 5 High Short Interest Stocks Getting Squeezed With Upside To Go
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.
